Prospective Double-Blind Study for the Use of Aspirin During Transurethral Surgery of the Bladder or the Prostate
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by University Hospital, Basel, Switzerland.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
University Hospital, Basel, Switzerland
Information provided by:
University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT00861367
First received: March 12, 2009
Last updated: NA
Last verified: March 2009
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Aspirin is very common in older patients. Therefore many of the investigators patients have aspirin. The aim of the study is to proof that Transurethral Surgery of the bladder or the prostate can be performed with aspirin.
| Condition | Intervention |
|---|---|
|
Blood Loss,Surgical; Intraoperative Complications; Reoperation Rates in Patients With Aspirin Treatment; |
Drug: transurethral surgery with or without aspirin |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Caregiver, Investigator) Primary Purpose: Prevention |
| Official Title: | Prospektive Doppel-Blind-Randomisierte Studie Zur Verwendung Von Aspirin Bei Transurethralen Operationen |
Resource links provided by NLM:
Further study details as provided by University Hospital, Basel, Switzerland:
Primary Outcome Measures:
- Blood loss [ Time Frame: intraoperative, 6 hours post op, 3 days postop ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Reoperation rates [ Time Frame: during hospitalization ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 124 |
| Study Start Date: | September 2008 |
| Estimated Study Completion Date: | December 2009 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
aspirin 100mg
|
Drug: transurethral surgery with or without aspirin
aspirin 100mg once a day, transurethral surgery with or without aspirin
Other Name: Asprin cardio 100mg
|
|
Placebo Comparator: 2
empty capsule
|
Drug: transurethral surgery with or without aspirin
aspirin 100mg once a day, transurethral surgery with or without aspirin
Other Name: Asprin cardio 100mg
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Transurethral surgery of the bladder or prostate, informed consent, age over 18
Exclusion Criteria:
- Oral anticoagulation,
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00861367
Locations
| Switzerland | |
| Urologische Universitätsklinik Basel-Liestal | |
| Liestal, Switzerland, 4410 | |
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
| Study Chair: | thomas C Gasser, Prof | Department of Urology, Liestal |
More Information
No publications provided
| Responsible Party: | Maurer Patrick/Dr., Department of Urology, Kantonsspital Liestal |
| ClinicalTrials.gov Identifier: | NCT00861367 History of Changes |
| Other Study ID Numbers: | 05/08 |
| Study First Received: | March 12, 2009 |
| Last Updated: | March 12, 2009 |
| Health Authority: | Switzerland: Ethikkommission |
Keywords provided by University Hospital, Basel, Switzerland:
|
aspirin blood loss transurethral surgery |
Additional relevant MeSH terms:
|
Hemorrhage Intraoperative Complications Blood Loss, Surgical Pathologic Processes Aspirin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents |
Therapeutic Uses Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Hematologic Agents Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Central Nervous System Agents |
ClinicalTrials.gov processed this record on June 18, 2013